This study may provide greater insights into the dedifferentiation features associated with TSHR expression in thyroid cancer and Kir5.1, which may be a potential therapeutic target in redifferentiation strategies for recurrent and metastatic thyroid cancer, thus enabling the adoption of RAI therapy and other treatments. This evidence concerns the gene TSHR and thyroid gland carcinoma.